Biopartners Submits Its Novel Interferon beta-1a, Biferonex(R), To The EMEA.BAAR, Switzerland -- Biopartners Holdings AG today announced that it has submitted a marketing authorization application for Biferonex([R]) (interferon beta-1a interferon beta-1a Avonex, Rebif Pharmacologic class: Biological response modifier Therapeutic class: Antiviral, immunoregulator Pregnancy risk category C Action) to the EMEA (Europe, Middle East, Africa) Refers to that region of the world. For example, one might see products packaged differently for the UK, EMEA and Asia Pacific markets. . Biferonex represents a fully innovative, pH neutral and human serum albumin serum albuminn. See seralbumin. (HSA HSA Health Savings Account (US) HSA Human Serum Albumin HSA Human Services Agency (Nevada) HSA Health Services Agency HSA Health and Safety Authority (Ireland) ) free formulation providing an optimized interferon beta interferon beta Fibroblast interferon IFN-β A 20 kD anti-viral protein with 30% 'homology' with IFN alpha, encoded on chromosome 9, produced by fibroblasts in response to viruses or polyribonucleotides treatment solution for patients suffering from relapsing remitting multiple sclerosis (RRMS RRMS Relapsing/Remitting Multiple Sclerosis RRMS Rosemont Ridge Middle School (West Linn, Oregon) RRMS Rocky Run Middle School (Virginia) RRMS Recoverable Resource Management Services ). The submission was welcomed by Professor O. R. Hommes, Chairman of the European Charcot Foundation which coordinates MS research in Europe. "Most impressive are the effects of Biferonex in reducing the size and the activity of inflammatory regions in the brain of MS patients as shown by MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. . This may reduce progression of the disease" he stated. Interferon beta has been extensively studied in multiple sclerosis, exhibiting beneficial effects in both the relapsing-remitting and progressive forms of the disease by inhibiting inflammatory activity and thereby reducing nerve cell damage. It is also thought to inhibit damage to the myelin sheath by both preventing a T cell-mediated auto-immune response to myelin myelin /my·elin/ (mi´e-lin) the lipid-rich substance of the cell membrane of Schwann cells that coils to form the myelin sheath surrounding the axon of myelinated nerve fibers. , and reducing the effect of other naturally-occurring compounds that can enhance the auto-immune response. The Biferonex HSA-free formulation boasts a low incidence of neutralizing antibodies (NABs) therefore optimizing drug treatment effectiveness. Additionally, its neutral pH minimizes the risk of injection site reactions, which should lead to an enhanced tolerability. About the MS market: The World Health Organization estimates that multiple sclerosis affects 2.5 million people worldwide and is one of the most common neurological disorders and causes of disability of young adults, especially in Europe and North America. About Biopartners Holdings AG Headquartered in Baar, Switzerland, with an affiliate in Germany, Biopartners is a global biopharmaceuticals company and a leader in the emerging field of multi-source biopharmaceuticals. Biopartners' mission is to develop biopharmaceuticals and innovative formulations of "first generation" biopharmaceuticals as well as advanced delivery systems that may improve patient compliance. Biopartners is developing a comprehensive range of biopharmaceutical products that may offer life-saving therapeutic benefits across many therapeutic areas. By now, Biopartners has submitted three dossiers to the EMEA and has a fourth product in phase III on the way. In March 2007, Biopartners was acquired by a Polish biotechnology company, Bioton S.A. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion